2008—2010年解放军第101医院口服抗糖尿病药应用分析  

Utilization of Oral Antidiabetic Drugs in PLA No.101 Hospital During 2008-2010

作　　者：潘小明[1] 陈云红[1] 叶光明[1] 

机构地区：[1]解放军第101医院药剂科,江苏无锡214044

出　　处：《中国医院用药评价与分析》2012年第1期31-33,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:了解我院3年来口服抗糖尿病药的应用情况及变化趋势,为临床合理用药提供参考。方法:对我院2008—2010年口服抗糖尿病药的销售金额、用药频度(DDDs)、限定日费用(DDC)等情况进行统计分析。结果:我院2008—2010年口服抗糖尿病药销售金额排序居前3位的是阿卡波糖片、格列奇特缓释片、格列美脲片;DDDs排序居前3位的是格列奇特片、格列吡嗪片、阿卡波糖片;DDC最低的是格列奇特片。结论:我院口服抗糖尿病药的使用基本合理,疗效肯定,质优价廉的药物深受临床医生和患者欢迎。OBJECTIVE ： To investigate the status quo and trend of the use of oral antidiabetic drugs in our hospital during 2008-2010 in order to provide references for rational use of oral antidiabetic drugs. METHODS ： The utilization of oral antidiabetic drugs in our hospital during 2008-2010 was analyzed statistically in respect of consumption sum, DDDs and DDC（defined daily cost）. RESULTS： The top 3 oral antidiabetic drugs on the consumption sum list were acarbose tablets, gliclazide sustained release tablets and glimepiride tablets, with gliclazide tablets, glipizide tablets and acarbose tablets leading the first 3 places in DDDs. The DDC of gliclazide tablets was the lowest. CONCLUSION： The use of oral antidiabetic drugs in PLA No. 101 Hospital was rational on the whole and the oral antidiabetic drugs with confirmed efficacy, good quality and low cost are deeply welcome by both clinicians and patients.

关 键 词：口服抗糖尿病药 用药频度 应用分析 

分 类 号：R977.15[医药卫生—药品]